-transparent.png){kind=logo}
6-Mercaptopurine (6-MP) is a cycle specific antineoplastic agent with a short serum half-life following bolus administration, providing a rationale for continuous infusional administration of the parenteral formulation. 22 patients received 38 courses of 14 day 6-MP infusion. The maximum tolerated dose (MTD) was 35 mg/m2/day (total dose per 14 day cycle 490 mg/m2) with cycles repeated at 28 days. Toxicities included transient hyperbilirubinaemia, leucopenia and thrombocytopenia. 13 evaluable patients with advanced colon cancer resistant to 5-fluorouracil with or without leucovorin received infusional 6-MP at the MTD as part of the phase II study analysis, but no objective responses were observed. Phase II studies in previously untreated patients and longer infusion durations are being evaluated.
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
October 1996,
European journal of cancer (Oxford, England : 1990),
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
November 1991,
Cancer research,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
November 1982,
Cancer treatment reports,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
January 1990,
European journal of cancer (Oxford, England : 1990),
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
September 1988,
Investigational new drugs,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
January 1981,
Cancer treatment reports,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
September 1995,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
August 1981,
European journal of cancer & clinical oncology,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
August 2005,
American journal of clinical oncology,
J Lokich, and
C Moore, and
N Anderson, and
M Bern, and
F Coco, and
E Dow, and
T Zipoli
January 1995,
Investigational new drugs,
